We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DPLM:LSEDiploma PLC Analysis

Data as of 2026-06-18 - not real-time

£7,040.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Diploma PLC has posted a solid interim earnings beat, lifting analyst price targets to £73.90 and sending the stock up 4.5% to £70.25. The share price sits above its 20‑day SMA (≈ £6,977) and the 50‑day SMA (≈ £6,888), confirming a short‑term bullish bias, while the 200‑day SMA (≈ £5,818) remains well below current levels, underscoring a longer‑term uptrend.
However, valuation metrics raise caution: the trailing P/E of 49.9 far exceeds the industry average of 31.2 and the DCF‑derived fair value of £45.2 k, indicating the stock is currently overvalued. Technical momentum is mixed – RSI sits at a neutral 56, MACD shows a bearish histogram, and volume is decreasing, hinting at waning buying pressure. Fundamentals remain resilient with 16.8% revenue growth, a healthy gross margin of 47.5%, and a dividend yield of 0.9% supported by a 44% payout ratio. The low beta (~0.28) suggests limited market‑wide volatility, yet 30‑day price volatility of 26% and thin trading volumes point to liquidity concerns. Overall, the company’s diversified geographic footprint mitigates regional risk, but the high valuation and sector cyclicality temper enthusiasm. Investors should weigh the strong earnings momentum and dividend against the overvaluation and liquidity constraints when deciding on position sizing.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish price above short‑term moving averages
  • Recent earnings beat and raised price target
  • Support level at £6,700 offering downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (16.8%) and expanding margins
  • Attractive dividend yield with sustainable payout
  • Forward P/E compression to 27.8 suggesting valuation improvement

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Current price well above DCF fair value
  • High overall valuation relative to peers
  • Sector cyclicality and elevated price volatility

Key Metrics & Analysis

Financial Health

Revenue Growth16.80%
Profit Margin11.50%
P/E Ratio49.9
ROE18.95%
ROA10.78%
Debt/Equity47.45
P/B Ratio9.0
Op. Cash Flow£283.9M
Free Cash Flow£244.3M
Industry P/E31.2

Technical Analysis

TrendBullish
RSI55.9
Support£6,700.00
Resistance£7,191.87
MA 20£6,976.99
MA 50£6,887.80
MA 200£5,817.87
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value£4,521.97
Target Price£7,703.75
Upside/Downside9.43%
GradeOvervalued
TypeGrowth
Dividend Yield0.90%

Risk Assessment

Beta0.28
Volatility26.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.